FAAH−/− Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Δ9-Tetrahydrocannabinol and Anandamide Administration
Open Access
- 31 March 2010
- journal article
- Published by Springer Science and Business Media LLC in Neuropsychopharmacology
- Vol. 35 (8), 1775-1787
- https://doi.org/10.1038/npp.2010.44
Abstract
Repeated administration of Delta(9)-tetrahydrocannabinol (THC), the primary psychoactive constituent of Cannabis sativa, induces profound tolerance that correlates with desensitization and downregulation of CB(1) cannabinoid receptors in the CNS. However, the consequences of repeated administration of the endocannabinoid N-arachidonoyl ethanolamine (anandamide, AEA) on cannabinoid receptor regulation are unclear because of its rapid metabolism by fatty acid amide hydrolase (FAAH). FAAH(-/-) mice dosed subchronically with equi-active maximally effective doses of AEA or THC displayed greater rightward shifts in THC dose-effect curves for antinociception, catalepsy, and hypothermia than in AEA dose-effect curves. Subchronic THC significantly attenuated agonist-stimulated [(35)S]GTP gamma S binding in brain and spinal cord, and reduced [(3)H]WIN55,212-2 binding in brain. Interestingly, AEA-treated FAAH(-/-) mice showed less CB(1) receptor downregulation and desensitization than THC-treated mice. Experiments examining tolerance and cross-tolerance indicated that the behavioral effects of THC, a low efficacy CB(1) receptor agonist, were more sensitive to receptor loss than those of AEA, a higher efficacy agonist, suggesting that the expression of tolerance was more affected by the intrinsic activity of the ligand at testing than during subchronic treatment. In addition, the CB(1) receptor antagonist, rimonabant, precipitated a markedly reduced magnitude of withdrawal in FAAH(-/-) mice treated subchronically with AEA compared with mice treated repeatedly with THC. The findings that repeated AEA administration produces lesser adaptive changes at the CB(1) receptor and has reduced dependence liability compared with THC suggest that pharmacotherapies targeting endocannabinoid catabolic enzymes are less likely to promote tolerance and dependence than direct acting CB(1) receptor agonists.Keywords
This publication has 48 references indexed in Scilit:
- Inhibitors of Endocannabinoid-Metabolizing Enzymes Reduce Precipitated Withdrawal Responses in THC-Dependent MiceThe AAPS Journal, 2009
- Sensitivity to Δ9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2−/− miceBehavioural Pharmacology, 2008
- Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brainNeuroscience, 2007
- Prolonged Recovery Rate of CB1 Receptor Adaptation after Cessation of Long-Term Cannabinoid AdministrationPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2006
- The cannabis withdrawal syndromeCurrent Opinion in Psychiatry, 2006
- Long-Term Administration of Δ9-Tetrahydrocannabinol Desensitizes CB1-, Adenosine A1-, and GABAB-Mediated Inhibition of Adenylyl Cyclase in Mouse CerebellumPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Signaling pathways involved in the development of cannabinoid toleranceTrends in Pharmacological Sciences, 2004
- Effect of Chronic Administration ofR-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone Mesylate (WIN55,212-2) or Δ9-Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in MiceJournal of Pharmacology and Experimental Therapeutics, 2002
- Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPγS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamideNeurochemistry International, 1999
- Clinical Relevance of Cannabis Tolerance and DependenceThe Journal of Clinical Pharmacology, 1981